TrialNeuro-oncology2014

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Brigitte C Widemann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.